CytoSorbents Investor Relations
CytoSorbents is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, with more than 300,000 CytoSorb® devices sold in more than 70 countries to date, and seeking U.S. FDA market authorization for an investigational product, DrugSorb-ATR®, to remove blood thinning drugs.
Featured News
CytoSorbents
Press Release
CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings
Patient-level matched analysis of real-world data demonstrated a significant 37% relative reduction in severe bleeding Significant reductions in 24-hour chest tube drainage and red blood cell transfusions were also seen, with no serious device-related adverse events reported Findings reinforce results from the STAR-T trial and are expected to form a core component of additional real-world ... CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings
CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
Presentation Listen to webcast CytoSorbents Reports Second Quarter 2026 Financial Results and Recent Business Highlights Presentation Listen to webcast
CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights
PRINCETON, N.J., July 20, 2026 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2026 financial results and recent business highlights after the market close on Thursday, August 6, 2026. CytoSorbents’ management will host a live ... CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights
CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026
PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present at the Life Sciences Forum hosted by VirtualInvestorConferences.com on Wednesday, June 24, 2026 and ... CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026
